Cancer-associated thrombosis (CAT) remains a leading cause of morbidity and mortality. Important risk factors in this population include chemotherapy, hormonal therapies, indwelling catheters or ports, immobility, and cancer-related hypercoagulability [1]. Cancer promotes thrombosis through inflammation, neutrophil extracellular transformation formation, endothelial activation, and treatment-related vascular injury, creating a persistent hypercoagulable state [2]. Extended anticoagulation is recommended beyond six months in patients with active malignancy in order to prevent recurrence of CAT [3].
